 Corey Lyon
Concepts (234)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Physicians, Family | 2 | 2022 | 173 | 1.140 |
Why?
| | Anticoagulants | 2 | 2025 | 721 | 0.990 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2024 | 2516 | 0.860 |
Why?
| | Osteoarthritis, Knee | 2 | 2018 | 279 | 0.860 |
Why?
| | Hypertension | 4 | 2022 | 1254 | 0.850 |
Why?
| | Glucocorticoids | 3 | 2018 | 533 | 0.810 |
Why?
| | Venous Thrombosis | 1 | 2025 | 194 | 0.780 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 2 | 2021 | 66 | 0.780 |
Why?
| | Medical Staff | 2 | 2022 | 17 | 0.770 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2020 | 267 | 0.770 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2024 | 108 | 0.730 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 919 | 0.720 |
Why?
| | Papillomavirus Infections | 2 | 2020 | 345 | 0.710 |
Why?
| | Metformin | 2 | 2023 | 315 | 0.710 |
Why?
| | Sphygmomanometers | 1 | 2021 | 6 | 0.690 |
Why?
| | Insulin, Isophane | 1 | 2021 | 22 | 0.680 |
Why?
| | Automation | 1 | 2021 | 102 | 0.660 |
Why?
| | Insulin Glargine | 1 | 2021 | 87 | 0.650 |
Why?
| | Humans | 56 | 2025 | 144261 | 0.650 |
Why?
| | Prediabetic State | 1 | 2023 | 243 | 0.640 |
Why?
| | Blood Pressure Determination | 1 | 2021 | 142 | 0.640 |
Why?
| | Employment | 1 | 2022 | 185 | 0.630 |
Why?
| | Preventive Health Services | 1 | 2022 | 152 | 0.630 |
Why?
| | Analgesia, Obstetrical | 1 | 2020 | 32 | 0.620 |
Why?
| | Smoking Cessation | 1 | 2024 | 439 | 0.620 |
Why?
| | Ganglion Cysts | 1 | 2020 | 10 | 0.620 |
Why?
| | Analgesia, Epidural | 1 | 2020 | 38 | 0.620 |
Why?
| | Aspirin | 2 | 2020 | 399 | 0.610 |
Why?
| | Papillomaviridae | 1 | 2020 | 115 | 0.610 |
Why?
| | Post-Concussion Syndrome | 1 | 2023 | 184 | 0.610 |
Why?
| | Early Detection of Cancer | 2 | 2022 | 462 | 0.610 |
Why?
| | C-Reactive Protein | 2 | 2021 | 416 | 0.600 |
Why?
| | Wrist | 1 | 2020 | 60 | 0.590 |
Why?
| | Diuretics | 1 | 2019 | 68 | 0.580 |
Why?
| | Spironolactone | 1 | 2019 | 39 | 0.580 |
Why?
| | Anti-Bacterial Agents | 2 | 2021 | 1906 | 0.580 |
Why?
| | Probiotics | 1 | 2019 | 61 | 0.570 |
Why?
| | Glucosamine | 1 | 2018 | 14 | 0.570 |
Why?
| | Ketorolac | 1 | 2019 | 30 | 0.570 |
Why?
| | Erythromycin | 1 | 2018 | 20 | 0.560 |
Why?
| | Memory | 1 | 2021 | 294 | 0.550 |
Why?
| | Rh-Hr Blood-Group System | 1 | 2018 | 14 | 0.550 |
Why?
| | Randomized Controlled Trials as Topic | 8 | 2023 | 1705 | 0.550 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 338 | 0.550 |
Why?
| | Glycemic Index | 1 | 2018 | 26 | 0.540 |
Why?
| | Viscosupplements | 1 | 2018 | 11 | 0.540 |
Why?
| | Sweating | 1 | 2018 | 41 | 0.540 |
Why?
| | Ureteral Calculi | 1 | 2018 | 16 | 0.540 |
Why?
| | Acute Pain | 1 | 2019 | 54 | 0.540 |
Why?
| | Musculoskeletal System | 1 | 2018 | 49 | 0.520 |
Why?
| | Hot Flashes | 1 | 2018 | 88 | 0.510 |
Why?
| | Antibiotic Prophylaxis | 1 | 2018 | 129 | 0.510 |
Why?
| | Obstetric Labor, Premature | 1 | 2017 | 39 | 0.500 |
Why?
| | Family Practice | 2 | 2018 | 403 | 0.500 |
Why?
| | Patient Education as Topic | 2 | 2022 | 777 | 0.500 |
Why?
| | Testosterone | 1 | 2021 | 419 | 0.500 |
Why?
| | Labor, Obstetric | 1 | 2017 | 66 | 0.490 |
Why?
| | Prenatal Diagnosis | 1 | 2018 | 195 | 0.480 |
Why?
| | Warfarin | 1 | 2017 | 170 | 0.480 |
Why?
| | Hypoglycemia | 1 | 2021 | 477 | 0.470 |
Why?
| | Melatonin | 1 | 2017 | 163 | 0.470 |
Why?
| | Analgesics | 1 | 2018 | 228 | 0.470 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2017 | 106 | 0.470 |
Why?
| | Methylprednisolone | 1 | 2016 | 64 | 0.460 |
Why?
| | Carpal Tunnel Syndrome | 1 | 2016 | 30 | 0.460 |
Why?
| | Hyaluronic Acid | 1 | 2018 | 208 | 0.460 |
Why?
| | Athletic Injuries | 1 | 2023 | 569 | 0.460 |
Why?
| | Telemedicine | 2 | 2022 | 940 | 0.460 |
Why?
| | Practice Guidelines as Topic | 4 | 2020 | 1559 | 0.460 |
Why?
| | Factor Xa Inhibitors | 1 | 2017 | 187 | 0.460 |
Why?
| | Job Satisfaction | 1 | 2018 | 240 | 0.460 |
Why?
| | Acute Coronary Syndrome | 1 | 2019 | 293 | 0.460 |
Why?
| | Migraine Disorders | 1 | 2017 | 112 | 0.450 |
Why?
| | Menopause | 1 | 2018 | 319 | 0.430 |
Why?
| | Brain Concussion | 1 | 2023 | 638 | 0.430 |
Why?
| | Cough | 1 | 2015 | 124 | 0.410 |
Why?
| | Drug Administration Schedule | 3 | 2025 | 778 | 0.410 |
Why?
| | Colorectal Neoplasms | 1 | 2022 | 844 | 0.400 |
Why?
| | Adrenal Cortex Hormones | 1 | 2017 | 478 | 0.400 |
Why?
| | Antioxidants | 1 | 2017 | 549 | 0.390 |
Why?
| | Respiratory Tract Diseases | 1 | 2015 | 175 | 0.390 |
Why?
| | Exercise Therapy | 1 | 2018 | 467 | 0.390 |
Why?
| | Myofascial Pain Syndromes | 2 | 2023 | 12 | 0.390 |
Why?
| | Acupuncture Therapy | 2 | 2023 | 21 | 0.380 |
Why?
| | Patient Care Team | 2 | 2018 | 686 | 0.380 |
Why?
| | Insulin | 1 | 2024 | 2501 | 0.380 |
Why?
| | Mass Screening | 2 | 2022 | 1332 | 0.380 |
Why?
| | Virus Diseases | 1 | 2015 | 216 | 0.370 |
Why?
| | Behavior Therapy | 3 | 2023 | 281 | 0.360 |
Why?
| | Low Back Pain | 2 | 2023 | 106 | 0.350 |
Why?
| | Health Promotion | 1 | 2018 | 774 | 0.340 |
Why?
| | Atrial Fibrillation | 1 | 2017 | 548 | 0.340 |
Why?
| | Cardiovascular Diseases | 2 | 2020 | 2134 | 0.330 |
Why?
| | Pain Measurement | 4 | 2023 | 552 | 0.310 |
Why?
| | Aged, 80 and over | 7 | 2021 | 8243 | 0.300 |
Why?
| | Fatty Acids, Omega-3 | 2 | 2020 | 142 | 0.270 |
Why?
| | Organizational Innovation | 2 | 2019 | 120 | 0.270 |
Why?
| | Aged | 10 | 2021 | 25850 | 0.260 |
Why?
| | Depression | 1 | 2017 | 1533 | 0.260 |
Why?
| | Abdomen, Acute | 1 | 2006 | 21 | 0.250 |
Why?
| | Female | 16 | 2023 | 77976 | 0.250 |
Why?
| | Papillomavirus Vaccines | 1 | 2010 | 297 | 0.250 |
Why?
| | Azithromycin | 2 | 2018 | 104 | 0.250 |
Why?
| | Pregnancy | 4 | 2022 | 7180 | 0.240 |
Why?
| | Enuresis | 1 | 2005 | 3 | 0.230 |
Why?
| | Deamino Arginine Vasopressin | 1 | 2005 | 13 | 0.230 |
Why?
| | Renal Agents | 1 | 2005 | 5 | 0.230 |
Why?
| | Middle Aged | 11 | 2021 | 35762 | 0.230 |
Why?
| | Treatment Outcome | 7 | 2021 | 11643 | 0.230 |
Why?
| | Hormone Replacement Therapy | 2 | 2023 | 106 | 0.200 |
Why?
| | Adult | 9 | 2022 | 40262 | 0.200 |
Why?
| | Fibromyalgia | 1 | 2023 | 51 | 0.190 |
Why?
| | Vaping | 1 | 2024 | 66 | 0.190 |
Why?
| | Age Factors | 2 | 2022 | 3313 | 0.190 |
Why?
| | Electronics | 1 | 2023 | 70 | 0.190 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2019 | 2026 | 0.180 |
Why?
| | Evidence-Based Medicine | 4 | 2019 | 729 | 0.180 |
Why?
| | Naltrexone | 1 | 2023 | 117 | 0.180 |
Why?
| | Occult Blood | 1 | 2022 | 40 | 0.180 |
Why?
| | Hypoglycemic Agents | 2 | 2024 | 1379 | 0.170 |
Why?
| | Lipid Regulating Agents | 1 | 2020 | 2 | 0.170 |
Why?
| | Life Style | 1 | 2023 | 475 | 0.170 |
Why?
| | Fish Oils | 1 | 2020 | 26 | 0.170 |
Why?
| | Postmenopause | 1 | 2023 | 391 | 0.170 |
Why?
| | United States | 5 | 2022 | 15876 | 0.160 |
Why?
| | Observational Studies as Topic | 1 | 2021 | 129 | 0.160 |
Why?
| | Hypertriglyceridemia | 1 | 2020 | 41 | 0.160 |
Why?
| | Labor Stage, Second | 1 | 2020 | 3 | 0.160 |
Why?
| | Time Factors | 2 | 2023 | 7155 | 0.160 |
Why?
| | Prenatal Care | 1 | 2022 | 306 | 0.160 |
Why?
| | Inpatients | 1 | 2024 | 542 | 0.150 |
Why?
| | Colonoscopy | 1 | 2022 | 260 | 0.150 |
Why?
| | Delivery, Obstetric | 1 | 2020 | 160 | 0.140 |
Why?
| | Ticlopidine | 1 | 2019 | 54 | 0.140 |
Why?
| | Systems Integration | 1 | 2018 | 36 | 0.140 |
Why?
| | Rho(D) Immune Globulin | 1 | 2018 | 6 | 0.140 |
Why?
| | Chondroitin Sulfates | 1 | 2018 | 35 | 0.140 |
Why?
| | Pain Management | 2 | 2023 | 405 | 0.140 |
Why?
| | Primary Health Care | 2 | 2019 | 1710 | 0.140 |
Why?
| | Venlafaxine Hydrochloride | 1 | 2018 | 12 | 0.140 |
Why?
| | Netherlands | 1 | 2018 | 82 | 0.140 |
Why?
| | Clostridium Infections | 1 | 2019 | 74 | 0.140 |
Why?
| | Primary Prevention | 1 | 2020 | 219 | 0.140 |
Why?
| | Proton Pump Inhibitors | 1 | 2019 | 109 | 0.140 |
Why?
| | Citalopram | 1 | 2018 | 32 | 0.140 |
Why?
| | Pneumonia, Bacterial | 1 | 2019 | 113 | 0.140 |
Why?
| | Arthralgia | 1 | 2018 | 61 | 0.130 |
Why?
| | Visual Analog Scale | 1 | 2018 | 34 | 0.130 |
Why?
| | Injections, Intra-Articular | 1 | 2018 | 58 | 0.130 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2018 | 44 | 0.130 |
Why?
| | Yoga | 1 | 2018 | 30 | 0.130 |
Why?
| | Patients | 1 | 2019 | 178 | 0.130 |
Why?
| | Male | 9 | 2021 | 72035 | 0.130 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 451 | 0.130 |
Why?
| | Prurigo | 1 | 2016 | 2 | 0.130 |
Why?
| | Estrogen Replacement Therapy | 1 | 2018 | 143 | 0.130 |
Why?
| | Community-Acquired Infections | 1 | 2019 | 174 | 0.130 |
Why?
| | Pain | 2 | 2023 | 777 | 0.120 |
Why?
| | Regression Analysis | 1 | 2019 | 998 | 0.120 |
Why?
| | Smoking | 1 | 2024 | 1468 | 0.120 |
Why?
| | Sulfonylurea Compounds | 1 | 2017 | 50 | 0.120 |
Why?
| | Nonprescription Drugs | 1 | 2017 | 65 | 0.120 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 434 | 0.120 |
Why?
| | Gastroesophageal Reflux | 1 | 2019 | 236 | 0.120 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2017 | 46 | 0.120 |
Why?
| | Blood Glucose | 2 | 2024 | 2312 | 0.120 |
Why?
| | Dietary Supplements | 1 | 2020 | 575 | 0.120 |
Why?
| | Recurrence | 1 | 2020 | 1134 | 0.120 |
Why?
| | Exanthema | 1 | 2016 | 84 | 0.120 |
Why?
| | Psychiatry | 1 | 2018 | 186 | 0.120 |
Why?
| | Prednisone | 1 | 2016 | 221 | 0.120 |
Why?
| | Injections | 1 | 2016 | 196 | 0.110 |
Why?
| | Administration, Oral | 1 | 2018 | 847 | 0.110 |
Why?
| | Diabetic Foot | 1 | 2015 | 25 | 0.110 |
Why?
| | Sleep | 1 | 2022 | 901 | 0.110 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2019 | 497 | 0.110 |
Why?
| | Acute Disease | 1 | 2018 | 1028 | 0.110 |
Why?
| | Achilles Tendon | 1 | 2015 | 35 | 0.110 |
Why?
| | Hemorrhage | 1 | 2020 | 809 | 0.110 |
Why?
| | Adolescent | 2 | 2025 | 22281 | 0.110 |
Why?
| | Burnout, Professional | 2 | 2019 | 484 | 0.110 |
Why?
| | Health Status | 1 | 2020 | 833 | 0.110 |
Why?
| | Quality of Health Care | 1 | 2019 | 688 | 0.110 |
Why?
| | Tendon Injuries | 1 | 2015 | 73 | 0.100 |
Why?
| | Pandemics | 1 | 2022 | 1682 | 0.100 |
Why?
| | Treatment Failure | 1 | 2015 | 363 | 0.100 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 1044 | 0.100 |
Why?
| | Sulfonamides | 1 | 2018 | 580 | 0.100 |
Why?
| | Hospitalization | 1 | 2024 | 2424 | 0.100 |
Why?
| | Double-Blind Method | 1 | 2018 | 2025 | 0.100 |
Why?
| | Administration, Inhalation | 1 | 2015 | 574 | 0.100 |
Why?
| | Gestational Age | 1 | 2017 | 975 | 0.100 |
Why?
| | Young Adult | 2 | 2023 | 13990 | 0.100 |
Why?
| | Skin Neoplasms | 1 | 2020 | 847 | 0.100 |
Why?
| | Osteomyelitis | 1 | 2015 | 143 | 0.100 |
Why?
| | Psychometrics | 1 | 2017 | 730 | 0.100 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 324 | 0.100 |
Why?
| | Alphapapillomavirus | 1 | 2010 | 35 | 0.080 |
Why?
| | Child | 3 | 2025 | 22537 | 0.080 |
Why?
| | Colorado | 2 | 2019 | 4562 | 0.080 |
Why?
| | Child, Preschool | 1 | 2025 | 11774 | 0.080 |
Why?
| | Mental Disorders | 1 | 2018 | 1138 | 0.070 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 2301 | 0.060 |
Why?
| | Prospective Studies | 1 | 2018 | 7970 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 6021 | 0.050 |
Why?
| | Diagnostic Imaging | 1 | 2006 | 338 | 0.050 |
Why?
| | Amitriptyline | 1 | 2023 | 24 | 0.050 |
Why?
| | Trigger Points | 1 | 2023 | 15 | 0.050 |
Why?
| | Blood Pressure | 2 | 2022 | 1759 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2015 | 3857 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1487 | 0.050 |
Why?
| | Dermoscopy | 1 | 2020 | 11 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2005 | 1050 | 0.040 |
Why?
| | Models, Organizational | 1 | 2019 | 143 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2022 | 509 | 0.040 |
Why?
| | Long-Term Care | 1 | 2019 | 117 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2018 | 197 | 0.030 |
Why?
| | Workflow | 1 | 2018 | 184 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1382 | 0.030 |
Why?
| | Skin | 1 | 2020 | 754 | 0.030 |
Why?
| | Blood Sedimentation | 1 | 2015 | 37 | 0.030 |
Why?
| | Rupture | 1 | 2015 | 91 | 0.030 |
Why?
| | Foot | 1 | 2015 | 100 | 0.030 |
Why?
| | Comorbidity | 1 | 2018 | 1646 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 623 | 0.020 |
Why?
| | Mental Health Services | 1 | 2018 | 459 | 0.020 |
Why?
| | Radiography | 1 | 2015 | 842 | 0.020 |
Why?
| | Prevalence | 1 | 2019 | 2815 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1983 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4278 | 0.020 |
Why?
| | Quality Improvement | 1 | 2018 | 1285 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 3637 | 0.020 |
Why?
| | Infant | 1 | 2022 | 10022 | 0.020 |
Why?
| | Risk Factors | 1 | 2017 | 10699 | 0.010 |
Why?
|
|
Lyon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|